Skip to content

Jan Smith

Jan Smith

Company: Revolution Medicines

Job title: Vice President, Biology


Jan is an experienced molecular pharmacologist with a focus in small molecule drug discovery across diverse target classes and therapeutic areas including oncology, CNS, gastrointestinal and respiratory diseases. She is currently VP, Head of Biology at Revolution Medicines a company focused on the development of new therapeutics for cancer patients through translation of frontier oncology targets. She has 20 years of research and development experience from Theravance Biopharma, and prior to that, Roche, leading the advancement of several novel drug candidates through discovery into early clinical Phase I/II development. Jan graduated from University of Bath, U.K., earned a Ph.D. from University of Cambridge, U.K. and conducted postdoctoral research at the University of California, Irvine and at the Sandoz Institute for Medical Research, London, U.K.


Panel Discussion: Advancing Successful Clinical Translation of RAS Targeted Therapies 2:30 pm

How to translate the promising science and the clear opportunity into safe and effective anti-RAS therapies? Routes for translational success from discovery to clinic: What will be the key factors for generating successful clinical results? What will investors look for in the next few years and what are the major challenges to be overcome in…Read more

day: Day Two

Translating Frontier Targets in the RAS Signaling Pathway to Outsmart Cancer 12:30 pm

SHP2 is upstream of KRAS but regulates key mutational drivers in the RAS pathway Targeting KRAS(GTP) may be superior to KRAS(GDP) inhibitors Effective and rational combinations are required to effectively abrogate emergent resistance mechanismsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.